LeMaitre to Participate at Upcoming Investor Conferences in March BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March. Leerink Partners Global Healthcare ConferenceTuesday, March 10, 2026W South Beach, MiamiManagement will present at 1:00 PM EDT Citizens Life Sciences ConferenceWednesday, March 11, 2026Eden Roc Miami Beach, MiamiManagement will present at 1:40 PM EDT Barclays Annual Global Healthcare ConferenceThursday, March 12, 2026Management wil...
A director at Edwards Lifesciences Corp sold 24,000 shares at 83.837USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted shar...
LeMaitre Q4 2025 Financial Results BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, ...
Occidental Announces Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced that it has commenced offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its outstanding senior notes and debentures listed in the table below and Consent Solicitations (as defined below) with respect to certain series of such senior notes and debentures, upon the terms and conditions described in Occidental’s Offer to Purchase and Consent Solicitation Statement, dated...
Occidental Announces Fourth Quarter 2025 Results HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its fourth quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website at . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Thursday, February 19, 2026, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (internat...
Integra LifeSciences Announces Key Executive Leadership Appointments Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, representing decades of experience in the MedTech industry PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead...
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026 BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online . All registrants will receive dial-in information and a PIN allowing them to access the li...
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026 PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on th...
A director at Stryker Corp sold 500,000 shares at 363.439USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services i...
A director at Boston Scientific Corp sold after exercising options/sold 160,901 shares at 93.495USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Stryker reports 2025 operating results and 2026 outlook Portage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2025: Fourth Quarter Results Reported net sales increased 11.4% to $7.2 billionOrganic net sales increased 11.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 100 bps to 30.2%Reported EPS increased 56.0% to $2.20Adjusted EPS(1) increased 11.5% to $4.47 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.